High b Value (2,000 s/mm2) Diffusion-Weighted Magnetic Resonance Imaging in Prostate Cancer at 3 Tesla: Comparison with 1,000 s/mm2 for Tumor Conspicuity and Discrimination of Aggressiveness
暂无分享,去创建一个
T. Sone | T. Tamada | N. Kanomata | Y. Jo | Y. Miyaji | H. Higashi | A. Yamamoto | Katsuyoshi Ito
[1] P. Grenier,et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. , 1986, Radiology.
[2] D. Le Bihan,et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.
[3] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[4] W. Fair,et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. , 1997, The Journal of urology.
[5] J Kurhanewicz,et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. , 1998, Radiology.
[6] J. Petrella,et al. Use of MR exponential diffusion-weighted images to eradicate T2 "shine-through" effect. , 1999, AJR. American journal of roentgenology.
[7] A. Elster,et al. Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. , 1999, Radiology.
[8] P. Babb,et al. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries , 2002, BJU international.
[9] P. Babb,et al. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons , 2002, BJU international.
[10] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[11] Y. Jo,et al. Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: A comparative study of 6 and 12 biopsy cores , 2006, International journal of urology : official journal of the Japanese Urological Association.
[12] B. K. Park,et al. Diffusion-Weighted Imaging of the Prostate at 3 T for Differentiation of Malignant and Benign Tissue in Transition and Peripheral Zones: Preliminary Results , 2007, Journal of computer assisted tomography.
[13] Masao Fukunaga,et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. , 2008, Radiology.
[14] John Kurhanewicz,et al. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. , 2008, Magnetic resonance imaging.
[15] M. Soloway,et al. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. , 2008, Urology.
[16] S. Fosså,et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population‐based study , 2009, BJU international.
[17] C. Kim,et al. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. , 2010, AJR. American journal of roentgenology.
[18] L. Kiemeney,et al. The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy , 2010, Histopathology.
[19] Chronic Disease Division. Cancer facts and figures , 2010 .
[20] Aytekin Oto,et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. , 2010, Radiology.
[21] T. Metens,et al. What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? , 2012, European Radiology.
[22] Baris Turkbey,et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.
[23] Thomas Hambrock,et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. , 2011, Radiology.
[24] T. Sone,et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. , 2011, AJR. American journal of roentgenology.
[25] A. Oto,et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. , 2011, AJR. American journal of roentgenology.
[26] S. Verma,et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.
[27] J. Fütterer,et al. ESUR prostate MR guidelines 2012 , 2012, European Radiology.
[28] G. Johnson,et al. Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. , 2012, Radiology.
[29] Takeshi Yoshikawa,et al. Clinical utility of apparent diffusion coefficient values obtained using high b‐value when diagnosing prostate cancer using 3 tesla MRI: Comparison between ultra‐high b‐value (2000 s/mm2) and standard high b‐value (1000 s/mm2) , 2012, Journal of magnetic resonance imaging : JMRI.
[30] Beom Jin Park,et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI , 2012, European Radiology.
[31] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[32] Masaaki Kawahara,et al. Diagnostic accuracy of ultra-high-b-value 3.0-T diffusion-weighted MR imaging for detection of prostate cancer. , 2012, Clinical imaging.
[33] D. Margolis,et al. MR spectroscopic imaging and diffusion‐weighted imaging of prostate cancer with Gleason scores , 2012, Journal of magnetic resonance imaging : JMRI.
[34] M. Moche,et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values , 2012, European Radiology.
[35] F. De Keyzer,et al. Genitourinary applications of diffusion-weighted MR imaging in the pelvis. , 2012, Radiology.
[36] P. P. Iu,et al. ESUR prostate MR guidelines. , 2013, European radiology.
[37] B. K. Park,et al. Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T , 2012, Korean journal of radiology.
[38] J. Babb,et al. Diffusion‐weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection , 2013, Journal of magnetic resonance imaging : JMRI.
[39] Makoto Obara,et al. Ultra‐high b‐value diffusion‐weighted MRI for the detection of prostate cancer with 3‐T MRI , 2013, Journal of magnetic resonance imaging : JMRI.
[40] Katsuyoshi Ito,et al. Diffusion‐weighted MRI and its role in prostate cancer , 2014, NMR in biomedicine.
[41] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.